GSK Investigational Site

Rimouski, Quebec G5L 5T1

0 studies enrolling now · 3 studies all time

What they study most

Diabetes Mellitus, Type 2, Nausea and Vomiting, Chemotherapy-Induced, Neoplasms, Head and Neck

Studies at this site

• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. — Completed
• Thiazolidinedione Intervention With Vitamin D Evaluation — Stopped early